Table 6. Adjusted Hazard Ratios of Sarcopenic Factors for Overall Survival and Progression-Free Survival by Multivariate Cox Proportional Hazard Analyses.
| Variables | Progression-free survival |
Overall survival |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| BMI (kg/m2) | ||||
| ≥ 18.5 | 1 (Reference) | 1(Reference) | ||
| < 18.5 | 1.11 (0.55 - 2.24) | 0.77 | 1.83 (0.79 - 4.21) | 0.16 |
| PMI (cm2/m2) | ||||
| High | 1 (Reference) | 1(Reference) | ||
| Low | 0.84 (0.48 - 1.48) | 0.56 | 1.05 (0.54 - 2.03) | 0.88 |
| IMAC | ||||
| High | 1 (Reference) | 1(Reference) | ||
| Low | 0.79 (0.38 - 1.67) | 0.54 | 0.43 (0.18 - 0.998) | 0.0496 |
| VSR | ||||
| High | 1 (Reference) | 1(Reference) | ||
| Low | 0.78 (0.42 - 1.46) | 0.44 | 0.72 (0.35 - 1.49) | 0.37 |
| VFA | ||||
| < 100 cm2 | 1 (Reference) | 1 (Reference) | ||
| ≥ 100 cm2 | 1.09 (0.64 - 1.84) | 0.75 | 1.22 (0.67 - 2.20) | 0.52 |
Multivariate adjustment for serum albumin (< 3.5 vs. ≥ 3.5 g/dL), neutrophil to lymphocyte ratio (< 5 vs. ≥ 5), ECOG-PS (0 - 1 vs. 2 - 4) and driver mutation of EGFR or ALK (wild-type vs. mutated). BMI: body mass index; CI: confidence interval; HR: hazard ratio; IMAC: intramuscular adipose tissue content; PMI: psoas muscle index; VFA: visceral fat area; VSR: visceral to subcutaneous adipose tissue area ratio; ECOG-PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase.